Abstract 743P
Background
CABO has been approved as first and further line therapy in pts with mRCC. No evidence is available about the efficacy of other drugs after CABO, and optimal therapeutic sequence is unknown.
Methods
We conducted a retrospective mono-institutional study in pts with mRCC who progressed after CABO. Demographics, disease data and therapeutic data were obtained from pts electronic medical records. We evaluated response rate (ORR), time to treatment failure (TTF) and overall survival (OS).
Results
Fifty-six pts received subsequent therapy after CABO (Table), with either axitinib (32%), immune checkpoint inhibitors (ICI, 32%), everolimus (29%), other targeted therapy (7%). Among 40 evaluable pts, disease control rate (DCR) was 43%: 14 (35%) [CE1] had stable disease and 3 (7,5%) partial responses: One pt with axitinib and 2 with ICI had PR (8%). DCR for axitinib, ICI, other TKI and everolimus and were respectively 60%, 46%, 43% and 30 %. Median TTF was 2.8 months (mo) in the entire cohort, 5.7mo for axitinib, 2.3mo for everolimus, 2.5 mo for ICI, and 3.5mo for other targeted agents. Table: 743P
| Variable | N=56 (%) |
| Male | 36(64%) |
| Age, median (range) | 62 (23-79) |
| Histology Clear Cell Papillary I / II Chromophobe Unclassified | 40 (71) 4 (7)/ 12 (13) 4 (7) 1(2%) |
| IMDC score Good Intermediate Poor Unknown | 11 (24 %) 24 (52%) 11 (24%) 10 |
| Previous ICI use (%) | 27 (48%) |
| Number of prior line ( including Cabo) | 1: 1 (1,8%) 2: 23 (41%) 3: 19 (33.9%) ≥4: 13 (23,2%) |
| Median OS | After cabo 9.7 mos |
| mTTF | Overall 2.8 mos Axi 5.7 mos Eve 2.3 mos ICB 2.8 mos |
Conclusions
Activity of subsequent treatment after CABO is limited. Patients treated with axitinib had numerically better outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Colomba-Blameble: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Ipsen; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy: Sanofi; Honoraria (self), Advisory/Consultancy: GSK; Travel/Accommodation/Expenses: Novartis. B. Escudier: Honoraria (self): Oncorena; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Bristol Myers Squibb; Honoraria (self), Advisory/Consultancy: EUSA pharma; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche/Genentech; Research grant/Funding (institution): BMS France. L. Albiges: Advisory/Consultancy, (inst): Amgen; Advisory/Consultancy, (inst): Astellas Pharma; Advisory/Consultancy, (inst): AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution), (inst): Bristol-Myers Squibb; Advisory/Consultancy, (inst): Corvus Pharmaceuticals; Advisory/Consultancy, (inst): Exelixis; Advisory/Consultancy, (inst): Ipsen; Advisory/Consultancy, (inst): Merck; Advisory/Consultancy, (inst): MSD; Advisory/Consultancy, (inst): Novartis; Advisory/Consultancy, (inst): Peloton Therapeutics; Advisory/Consultancy, (inst): Roche; Advisory/Consultancy, (inst): Pfizer. All other authors have declared no conflicts of interest.